Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.
Explore this paper's citation graph
Summary
In mice with obesity-associated upregulated hepatic peroxisome proliferator-activated receptor-gamma expression, thiazolidinediones may produce hepatic steatosis.
- Type
- article
- Published
- 2001-07-01
- Cited by
- 174
- References
- 30
- OpenAlex
- https://openalex.org/W1978677356
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:35546575
Keywords
Steatosis, Endocrinology, Internal medicine, Rosiglitazone, Peroxisome proliferator-activated receptor
References
- PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene.
- Genetic organization of the agouti region of the mouse.
- Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and beta-oxidation in fructose-fed rats.
- Troglitazone action is independent of adipose tissue.
- General survey of diabetic features of yellow KK mice.
- Terminal differentiation of human breast cancer through PPAR gamma.
- Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes.
- Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.
- Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats.
- Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis
- Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.
- Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL KsJ-db db mice
- Body composition and hepatic steatosis as precursors for fibrotic liver disease
- Pioglitazone: in vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAy mice.
- Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator–Activated Receptors and Liver X Receptor-α in Humans: No Alteration in Adipose Tissue of Obese and NIDDM Patients
- Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis.
- The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers.
- Quantitative real-time PCR for the measurement of feline cytokine mRNA
- Up-Regulation of Peroxisome Proliferator-Activated Receptors (PPAR-α) and PPAR-γ Messenger Ribonucleic Acid Expression in the Liver in Murine Obesity: Troglitazone Induces Expression of PPAR-γ-Responsive Adipose Tissue-Specific Genes in the Liver of Obese Diabetic Mice* * This work was supported by
- Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol.
Cited by
- Overexpression of APOC1 in obob mice leads to hepatic steatosis and severe hepatic insulin resistance Published, JLR Papers in Press, October 1, 2003. DOI 10.1194/jlr.M300240-JLR200
- Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury.
- Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man
- Fish oil prevents excessive accumulation of subcutaneous fat caused by an adverse effect of pioglitazone treatment and positively changes adipocytes in KK mice
- Fatty acid and glucose metabolism in upper body obesity : effects of diet and exercise compared to pioglitazone administration
- Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver
- Effect of Chronic Pioglitazone Treatment on Hepatic Gene Expression Profile in Obese C57BL/6J Mice
- Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse.
- EFECTO DE LA EXPOSICIÓN INTRA ÚTERO A BISFENOL-A EN LA HOMEOSTASIS DE LA GLUCOSA EN RATONES.
- Mechanisms by which the thiazolidinedione troglitazone protects against sucrose‐induced hepatic fat accumulation and hyperinsulinaemia
- Combination effects of pioglitazone and bofutsushosan on body weight and blood glucose levels in diabetic KKAy mice
- Hepatic effects of rosiglitazone in rats with the metabolic syndrome.
- FoxO6 integrates insulin signaling with MTP for regulating VLDL production in the liver.
- Protopanaxatriol, a novel PPARγ antagonist from Panax ginseng, alleviates steatosis in mice
- Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity.
- DHEA and non-alcoholic fat liver disease: increased gene expression of peroxisome proliferation-activated receptor γ (PPARγ) and fatty acid synthase (FAS)
- Intraperitoneal administration attenuates thiazolidinedione-induced hepatic steatosis in KKAy mice with increased hepatic peroxisome proliferator-activated receptor (PPAR)γ mRNA expression.
- Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.
- Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside
- Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury.
Related papers
- The comparison study of pioglitazone and rosiglitazone on type 2 diabetes with hyperlipemia
- Cardiovascular safety of rosiglitazone and pioglitazone
- Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?
- Rosiglitazone and Pioglitazone for the Treatment of Alzheimer's Disease
- Dyslipidaemia in Type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone
- Pioglitazone vs. Rosiglitazone in Older Patients with Type 2 Diabetes
- The safety of thiazolidinediones
- Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study
- The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: a meta-analysis.
- Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.